Finn
ZTS Animal Health · Large cap · Pet care · Livestock · Thesis updated November 15, 2026

Aggressive discounts slow Zoetis market share loss but pressure margins

01 Running thesis

Defending volume at all costs

Zoetis still has a strong base. It sells trusted animal medicines, vaccines, and diagnostics across pets and livestock. It also has scale, a large sales force, and more than 5,500 patents. That gives the company real staying power.

The problem is that the most important engine is stalling hard. In Q3 2026, U.S. segment revenue fell 6 percent. To stop losing customers to competitors, Zoetis is rolling out aggressive discounts, rebates, and bundling. This defensive strategy slowed share loss in dermatology to 4 points in Q3, down from 7 points in Q2. However, it protects sales volume at the direct expense of profit margins.

The bull case relies on livestock and international markets continuing to offset U.S. weakness. A recovery also needs the upcoming launches of long-acting Cytopoint and Simparica Duo to succeed and the new pricing strategy to avoid structurally ruining profit margins.

The bear case remains active. The overall market is not expanding. Management set a cautious tone for 2027 and expects continued competitive pressure. The key question is whether these heavy promotions cause a permanent race to the bottom on pricing.

Nov 2026→Q3 2026 results showed defensive pricing slowing U.S. dermatology share loss, though U.S. segment revenue still declined 6 percent. Management narrowed full-year guidance to a 1 percent to 2 percent operational decline.
Aug 2026▼Q2 2026 results confirmed a worsening U.S. environment. Management cut full-year organic operational revenue guidance to negative 1 percent to 3 percent and noted aggressive discounting to defend volume.
May 2026▼Q1 2026 confirmed a sharper U.S. slowdown. U.S. revenue fell 8 percent, U.S. companion animal revenue fell 11 percent, and management cut full-year organic operational revenue growth guidance to 2 percent to 5 percent.
Feb 2026▼Initial 2026 guidance pointed to slower growth than Zoetis has delivered in stronger periods. Management also said the OA pain franchise was showing signs of stabilization, keeping a recovery path open.
Nov 2025▼Q3 2025 showed flat operational revenue growth and a sharp decline in the OA pain franchise. Management blamed part of the pressure on online concerns and said it expected recovery work to show results in 2026.
Aug 2025▼Q2 2025 showed operational revenue growth slowing to 5 percent, with lower U.S. sales for Librela and Solensia. The update made the pain franchise a bigger watch item.
02 Business model

Vet trust meets price sensitivity

Zoetis discovers, makes, and sells animal health products. Most are medicines, vaccines, and diagnostics for veterinarians and livestock producers. The company works in both the companion animal and livestock markets.

The model relies heavily on veterinarians, who prescribe the treatments and influence pet owners. Zoetis supports them with a large direct sales force and technical specialists who teach customers how to use the products correctly.

The strategy usually involves launching premium products to treat unmet needs. Right now, this model is under severe pressure. Pet owners are pushing back on price, forcing Zoetis to offer steep discounts and rebates to keep its market share in an environment where competitors are taking volume.

Product concentration adds risk. A few top lines like Simparica and Apoquel generate a massive chunk of revenue. If competitors take share or force price cuts in these specific areas, total company profits fall.

03 Product portfolio

The franchises that matter

Growth engine

Simparica franchise

This parasiticide line protects pets from fleas, ticks, and related parasites. It faces intense U.S. competition and price sensitivity.

Cash cow

Apoquel

Apoquel is a major dermatology product for itchy skin and allergic disease in dogs. Zoetis is using gross-to-net investments to defend its volume.

Steady

Cytopoint

Cytopoint adds breadth to the pet allergy franchise. Investors are watching for the approval of a long-acting version by year-end to revive growth.

Option

Librela and Solensia

These osteoarthritis pain antibody products opened a newer market for dogs and cats. The franchise has struggled, and the recovery path remains uncertain.

Steady

Vaccines

Vaccines serve both companion animals and livestock. International companion animal vaccine demand provides useful stability.

Steady

Livestock medicines

Zoetis sells anti-infectives and other medicines for cattle, swine, poultry, and fish. Livestock revenue grew 7 percent globally in Q3 2026, serving as a critical offset to U.S. pet weakness.

04 Business segments

Two big markets, one weak spot

United States52%declining
International48%modest

Mix is based on Q3 2026 revenue disclosures, where the U.S. segment represented roughly $1.2 billion and International represented $1.1 billion.

05 Risk factors

What could break the thesis

Margin destruction from discounts

High impact · High odds

Zoetis is using aggressive gross-to-net pricing investments like rebates, bundling, and promotions to defend market share. This sacrifices profitability. If competitors match these cuts, it could trigger a race to the bottom on pricing.

We watchGross margin trends and management comments on promotional intensity.

U.S. pet demand stays weak

High impact · High odds

The U.S. segment fell 6 percent in Q3 2026, dragged down by companion animal declines. If pet owners keep pulling back on spending or trading down from premium products, the entire company's growth profile will suffer.

We watchQuarterly U.S. companion animal revenue growth and comments on vet clinic traffic.

Competition stops growing the market

High impact · High odds

Zoetis used to benefit when innovation expanded animal health categories. New entrants are not expanding the overall market in the same way right now. That raises the risk of pure share loss and discounting.

We watchPrice and volume trends for Simparica, Apoquel, and Cytopoint.

Top product concentration bites

High impact · Medium odds

The top five product lines represent about 42 percent of revenue. A problem in a few big lines, like generic competition for older drugs or safety concerns for newer ones, can move total company results dramatically.

We watchGrowth rates for the top five product lines and generic entry updates.

Librela recovery fails

Medium impact · Medium odds

Librela and Solensia were meant to be major growth products in pet osteoarthritis pain. The franchise has faced headwinds. If the company cannot rebuild confidence and drive adoption, the pain opportunity will stay small.

We watchQuarterly Librela and Solensia revenue.
06 Quick answers

In one breath

What does Zoetis do?

Zoetis makes and sells animal health products. Its main areas include medicines, vaccines, diagnostics, and related services for pets and livestock.

Why is Zoetis under pressure in 2026?

The biggest issue is the U.S. companion animal business. Management points to lower vet traffic, price-sensitive pet owners, and tougher competition forcing the company to heavily discount products to keep customers.

Is Zoetis only a pet company?

No. Companion animal products are the larger part of the business, but Zoetis also sells livestock products for cattle, swine, poultry, and fish. In Q3 2026, global livestock grew 7 percent and was much stronger than the U.S. pet business.

What should investors watch next?

Watch whether Q4 results show that the aggressive discounts completely stabilized U.S. dermatology market share. Also watch the approvals and launches of long-acting Cytopoint and Simparica Duo.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Zoetis Q3 2026 earnings call transcript
  2. Zoetis Q2 2026 Form 10-Q
  3. Zoetis Q1 2026 Form 10-Q
08 Explore the industry

Comparable Drug Manufacturers - Specialty & Generic companies

Companies near Zoetis Inc. in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

Get started with Finn today